JP2024516392A - 抗体定常領域バリアントを有する結合分子の多量体化 - Google Patents

抗体定常領域バリアントを有する結合分子の多量体化 Download PDF

Info

Publication number
JP2024516392A
JP2024516392A JP2023565419A JP2023565419A JP2024516392A JP 2024516392 A JP2024516392 A JP 2024516392A JP 2023565419 A JP2023565419 A JP 2023565419A JP 2023565419 A JP2023565419 A JP 2023565419A JP 2024516392 A JP2024516392 A JP 2024516392A
Authority
JP
Japan
Prior art keywords
antigen
igg
human
molecule
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023565419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516392A5 (https=
Inventor
チェン ルジン
ファン ビン
ハンセン サイモン
Original Assignee
エヌジーエム バイオファーマシューティカルス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エヌジーエム バイオファーマシューティカルス，インコーポレーテッド filed Critical エヌジーエム バイオファーマシューティカルス，インコーポレーテッド
Publication of JP2024516392A publication Critical patent/JP2024516392A/ja
Publication of JP2024516392A5 publication Critical patent/JP2024516392A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023565419A 2021-04-28 2022-04-27 抗体定常領域バリアントを有する結合分子の多量体化 Withdrawn JP2024516392A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163180969P 2021-04-28 2021-04-28
US63/180,969 2021-04-28
PCT/US2022/026505 WO2022232246A1 (en) 2021-04-28 2022-04-27 Multimerization of binding molecules having an antibody constant region variant

Publications (2)

Publication Number Publication Date
JP2024516392A true JP2024516392A (ja) 2024-04-15
JP2024516392A5 JP2024516392A5 (https=) 2025-05-02

Family

ID=83847261

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565419A Withdrawn JP2024516392A (ja) 2021-04-28 2022-04-27 抗体定常領域バリアントを有する結合分子の多量体化

Country Status (7)

Country Link
US (1) US20240209116A1 (https=)
EP (1) EP4330277A4 (https=)
JP (1) JP2024516392A (https=)
CN (2) CN117255800A (https=)
AU (1) AU2022266780A1 (https=)
CA (1) CA3216755A1 (https=)
WO (1) WO2022232246A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4206226A4 (en) * 2020-08-31 2024-10-16 Medytox Inc. Anti-vegf hexameric antibody and composition comprising same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6509724B2 (ja) * 2012-04-20 2019-05-08 アプティーボ リサーチ アンド デベロップメント エルエルシー Ｃｄ３結合ポリペプチド
CN104736174B (zh) * 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
JP2015524821A (ja) * 2012-08-02 2015-08-27 ジェイエヌ バイオサイエンシーズ エルエルシー システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質
JP6685924B2 (ja) * 2014-04-11 2020-04-22 メディミューン，エルエルシー システイン操作抗体を含むコンジュゲート化合物
KR20180002653A (ko) * 2015-04-07 2018-01-08 제넨테크, 인크. 효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법

Also Published As

Publication number Publication date
CN118359707A (zh) 2024-07-19
WO2022232246A1 (en) 2022-11-03
US20240209116A1 (en) 2024-06-27
AU2022266780A9 (en) 2023-11-16
EP4330277A1 (en) 2024-03-06
CN117255800A (zh) 2023-12-19
EP4330277A4 (en) 2025-03-26
AU2022266780A1 (en) 2023-11-09
CA3216755A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
JP7504347B2 (ja) Ｃｌａｕｄｉｎ１８．２結合部分及びそれらの使用
US20180289802A1 (en) Formulations comprising pd-1 binding proteins and methods of making thereof
US20240182582A1 (en) Materials and methods for immune effector cells redirection
CA3222788A1 (en) Depletion of activated hepatic stellate cells (hscs) and uses thereof
US20250230254A1 (en) Biosynthetic bioparatopic or bispecific binding molecules with enhanced effector functions
US20250011454A1 (en) Biosynthetic monovalent binding molecules with enhanced effector functions
US20240209116A1 (en) Multimerization of binding molecules having an antibody constant region variant
IL303610A (en) GUCY2C binding molecules and their uses
WO2023240067A2 (en) Multimerization of binding molecules having an antibody constant region variant and mutations that reduce effector functions
TW202337904A (zh) ＩＬ－１β結合蛋白之材料及方法
US20240218083A1 (en) Molecules with engineered antibody constant region variants
EP4294846A1 (en) Materials and methods for targeting regulatory t cells for enhancing immune surveillance
CN117545505A (zh) 具有工程化抗体恒定区变体的分子
CN121002064A (zh) 抗lilrb1和/或抗lilrb2抗体及其用途
EP4554969A1 (en) Material and methods for improved bioengineered pairing of antigen-binding variable regions
CN121909215A (zh) 抗acvr2b抗体及其用途
CN117500836A (zh) 用于免疫效应细胞重定向的材料和方法
HK40119194A (zh) IL-1β结合蛋白的材料和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250422

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250523